NCT06038630

129Xe MRI Cardiopulmonary

129Xe Gas Exchange MRI to Visualize Cardiopulmonary Function

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 125 (estimated)
• Sponsor: Bastiaan Driehuys · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.

Detailed description

This study focuses on the markers that are derived from the interaction of 129Xe with pulmonary capillary red blood cells (RBCs). Specifically, the investigators focus on RBC transfer MRI, cardiogenic oscillations in 129Xe-RBC signal amplitude, and the 129Xe-RBC chemical shift. In addition to healthy volunteers, the population to be studied will consist of patients scheduled to undergo either transfusion or phlebotomy, those with dyspnea, those with a physician diagnosis of interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonias (NSIP), chronic hypersensitivity pneumonitis (cHP), and sarcoid, as well as those with either chronic thromboembolic pulmonary hypertension (CTEPH) and acute pulmonary embolism.

Conditions

• Interstitial Lung Disease
• Chronic Thromboembolic Pulmonary Hypertension
• Acute Pulmonary Embolism
• Anemia
• Polycythemia
• Dyspnea

Interventions

Type	Name	Description
DRUG	Hyperpolarized Xe129	Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.
OTHER	Oxygen Administration	Oxygen administration

Timeline

• Start date: 2024-01-12
• Primary completion: 2028-06-30
• Completion: 2028-06-30
• First posted: 2023-09-15
• Last updated: 2026-02-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study